enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The company is headquartered in Saint-Laurent, Canada.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-135.93M |
| Operating Margin | 0.00% |
| Return on Equity | -60.50% |
| Return on Assets | -32.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.44 |
| Price-to-Book | 0.58 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -6.01 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $67.02M |
| Float | $32.75M |
| % Insiders | 0.11% |
| % Institutions | 83.75% |
Volatility is currently expanding
enGene NASDAQ: ENGN used a company webinar to outline preclinical findings for its investigational non-viral gene therapy, detalimogene voraplasmid, used with a polidocanol surfactant bladder rinse, while community urologists discussed the treatment burden facing patients with high-risk non-muscle invasive bladder cancer, or NMIBC.
enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a webinar on Thursday, October 15, 2026 at 10:00 AM ET that will provide greater detail on the preclinical data supporting the incorporation of its surfactant bladder rinse plus detalimogene voraplasmid (detalimogene) into clinical development for Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, no.
enGene Therapeutics remains deeply undervalued, trading below its $3.97/share cash position despite pipeline and execution risks. ENGN's lead asset, detalimogene voraplasmid, faces FDA approval risk due to weak 12-month durability, but management is pursuing a surfactant cohort to address efficacy. Cost-saving measures, including a 50% workforce reduction, extend ENGN's cash runway into 2029, supporting operations through pivotal BLA milestones.
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter ended July 31, 2026, and provided clinical and corporate updates. “As we move through the second half of 2026, our focus is on maturing regulatory endpoints data from LEGEND's pivotal cohort and our planned engagement with the FDA regarding a BLA filing for detalimogene," said Ro.
enGene NASDAQ: ENGN outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a larger addressable patient population and greater use of treatment sequencing before radical cystectomy.
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the appointment of Constantine Chinoporos as Executive Chairman of the company's board of directors, effective immediately.
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced its financial results for the second quarter ended April 30, 2026, and provided clinical and corporate updates. “Feedback from the urology community on the emerging detalimogene without surfactant profile, presented at the AUA meeting in May, supports our plan to await mature durability data in the second half of 2026 and m.
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene Therapeutics Inc. ("enGene" or "the Company") (NASDAQ: ENGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene Therapeutics Inc. ("enGene" or "the Company") (NASDAQ: ENGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ENGN and any ticker you trade — then tracks every position and per-strategy win rate.
